Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight New York, USA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight The rising prevalence of urticaria...

Chronic Urticaria Competitive Landscape Assessment 2024: Regeneron/Sanofi (Dupixent) and Genentech/Novartis (Xolair) Dominate the Market Dublin, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The "Chronic Urticaria: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.This report provides a data-driven overview of...

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of...

InflaRx Hosts R&D Event Highlighting the Promise of INF904 Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential...

Global Vitiligo Treatment Market 2023: Unpacking the Potential of Antihistamines, H2 Antagonists and Tricyclic Antidepressants Dublin, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment Global Market Report 2023" has been added to ResearchAndMarkets.com's offering. The global vitiligo treatment market is expected...